EyeQDirectory

Official company dossier

Atomic AI

AI Expert

Biotechnology Companiesatomic.aiUS

AI Trust Score, Reviews & Company Verification

Ownership opportunity

Is this your company? Claim the Atomic AI profile to verify ownership and manage company-provided details.

Independent company assessment

8.8/10B · Solid

24 indexed evidence signals reviewed

AI Comparison

Safe Entity63% Confidence

Based on 5 polled AI models

  • GeminiGoogle DeepMind
    Safe80%Confidence
  • GrokxAI
    Safe68%Confidence
  • DeepSeekDeepSeek
    Mixed40%Confidence
  • GLMZ.ai
    Mixed55%Confidence
Updated Jul 29
Profile not verified by the brand
Unclaimed profile

This profile is waiting for Atomic AI

Atomic AI has not claimed this ShouldEye profile yet.

Until an authorized representative verifies ownership, ShouldEye AI independently maintains this overview from public records, reviews, regulatory filings, and live trust signals. Nothing on this page has been approved by the brand.

AI-maintained · Not brand-verified

  • Respond to reviews and experiences in your voice
  • Replace this placeholder with your official brand message
  • Take control of how your trust score is presented

Free verification for authorized company representatives

About

Atomic AI is a biotechnology company that combines machine learning with structural biology to design RNA‑targeted small molecules and RNA‑based therapeutics.

Headquarters
US
EyeQ
EyeQ AI Live

Full intelligence report for Atomic AI

High confidence

Atomic AI demonstrates strong governance and a well-regarded reputation, backed by solid privacy practices and largely positive customer feedback. Its advertising transparency, customer service, and domain integrity, while adequate, sit noticeably below its top-tier signals and point to operational areas where execution could tighten. Overall, the company holds a verified, fundamentally sound trust profile that should reassure consumers, though addressing those mid-tier gaps would better align its day-to-day operations with its high compliance standards.

Strengths
  • Secured $35 million Series A funding and total $42 million from prominent investors
  • CEO recognized in Forbes 30 Under 30 for Science in 2023
  • Leverages cutting‑edge AI and structural biology for RNA drug discovery with a strong scientific foundation and advisory board
Key Risks
  • Privacy policy omits clear limits on indefinite retention of user comments and metadata
  • Lacks transparency about data usage for AI/ML training
  • Does not include data breach notification procedures or a direct mechanism for data deletion, relying on user requests
Domain & infrastructure
—Domain registrar
—Domain age
5 assetsVerified assets
Contact & Support
People Behind Atomic AI

Discovering leadership team…